search
Back to results

Complex Exercises of the Respiratory Muscles Plus Aerobic Training vs. Aerobic Training in Patients With СHF (AEROFIT-HF)

Primary Purpose

Heart Failure

Status
Completed
Phase
Not Applicable
Locations
Russian Federation
Study Type
Interventional
Intervention
respiratory muscles training
sham respiratory muscles training
aerobic training
Sponsored by
Lomonosov Moscow State University Medical Research and Educational Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Failure focused on measuring CHF, exercise, aerobic, respiratory muscle training

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male and female patients aged 18 years and older (inclusive)
  • Patients with stable heart failure of the II-III functional class.
  • Signed patient informed consent to participate in the study.
  • Left ventricular ejection fraction ≤40%, confirmed by the results of EchoCG no more than 3 months before the start of the study.
  • Patients who can understand the objectives of this study and comply with the requirements of the Protocol.

Exclusion Criteria:

  • • Heart failure I and VI functional class

    • Left ventricular ejection fraction> 41% or no confirmed data on the left ventricular EF.
    • Myocardial infarction, ACS, heart surgery, percutaneous coronary intervention, or coronary artery bypass surgery performed less than 3 months prior to randomization.
    • Unstable or refractory angina.
    • Pulmonary heart.
    • Constrictive pericarditis.
    • Hypertrophic cardiomyopathy.
    • Amyloid cardiomyopathy.
    • Syndrome of premature excitation of the ventricles.
    • The need for percutaneous coronary intervention or coronary bypass surgery in the near future.
    • Sinus node dysfunction syndrome.
    • The presence of a pacemaker.
    • The presence of diagnosed non-cardiac causes of CHF.
    • Any non-cardiac disease that reduces the expected duration to less than 2 years from the moment of randomization.
    • A stroke less than 1 month prior to randomization or a stroke with marked continuing neurological disorders less than 12 months before randomization
    • Orthopedic disorders that prevent physical training
    • COPD, Bronchial asthma. Another lung disease that can affect CSTP results
    • Significant impaired renal function (plasma creatinine 220 µmol / L or higher).
    • Significant abnormal liver function (increased ALT or AST more than 3 times relative to the upper limit of normal).
    • Acute coronary syndrome less than 3 months before randomization.
    • Obstructive or restrictive cardiomyopathy.
    • Acute myocarditis.
    • Hemodynamically significant organic lesions of valves requiring surgical intervention.
    • A history of heart transplantation or current waiting for a heart transplant.
    • Drug addiction, substance abuse, alcoholism, drug use in history.
    • Mental, physical and other reasons that do not allow to adequately assess their behavior and correctly fulfill the conditions of the study protocol.
    • A history of any significant, in the opinion of the physician-researcher, condition / disease or circumstances that prevent the inclusion in the study.
    • Inability / reluctance of the patient to provide signed informed consent to participate in the study.

Sites / Locations

  • Julia Begrambekova

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

respiratory muscles training

sham respiratory muscles training

Arm Description

4 weeks guided respiratory muscles training followed by 12 weeks guided aerobic training - (treadmill walking)

4 weeks sham respiratory muscles training (THRESHOLD® IMT breathing trainer with "0" pressure level) followed by 12 weeks guided aerobic training - (treadmill walking)

Outcomes

Primary Outcome Measures

Functional Capacity
Change in Peak VO2

Secondary Outcome Measures

proBNP
Change in concentration of NT- proBNP from baseline
proBNP
Change in concentration of NT- proBNP from baseline
Respiratory muscle strength
Change in maximal inspiratory and expiratory pressures (PImax and PEmax) from baseline
Respiratory muscle strength
Change in maximal inspiratory and expiratory pressures (PImax and PEmax) from baseline
Neurohormone activity
Difference between Active and Control groups in Angiotensin II (A II) concentration from baseline
Neurohormone activity
Change in concentration of Angiotensin II (A II) from baseline

Full Information

First Posted
October 30, 2018
Last Updated
November 21, 2022
Sponsor
Lomonosov Moscow State University Medical Research and Educational Center
Collaborators
Russian Heart Failure Society
search

1. Study Identification

Unique Protocol Identification Number
NCT03726905
Brief Title
Complex Exercises of the Respiratory Muscles Plus Aerobic Training vs. Aerobic Training in Patients With СHF
Acronym
AEROFIT-HF
Official Title
Effectiveness and Safety of Complex Exercises of the Respiratory Muscles Plus Aerobic Training vs. Aerobic Training in Patients With CHF and II-IV NYHA FC: Prospective Randomized Clinical Trial With Sham Control
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Completed
Study Start Date
November 30, 2018 (Actual)
Primary Completion Date
December 1, 2020 (Actual)
Study Completion Date
December 30, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lomonosov Moscow State University Medical Research and Educational Center
Collaborators
Russian Heart Failure Society

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The aim of the study is to test the hypothesis that the physical rehabilitation starting with respiratory training followed by the aerobic exercises will have a more pronounced effect on clinical and functional indicators than the currently used physical rehabilitation based on aerobic training alone
Detailed Description
Changes in the respiratory muscles play an important role in the pathophysiology of exercise intolerance in CHF patients. The weakness of the respiratory muscles leads to a decrease in the efficiency of breathing and the formation of a pathological type of breathing, in which the inhalation time is prolonged, and the expiration time is shortened. Patients with weak respiratory muscles have impaired functional status, as determined by peak oxygen consumption. The violation of the ratio of inspiratory time / to the total time of the respiratory cycle is associated with an increase in the activity of the sympathoadrenal system. The positive effect of respiratory muscle training on MIP, MEP, peak VО 2, VE, VE / VCO 2 slope, VE oscillation, rhythm variability, and quality of life parameters is shown. Decreased oxygenation of the respiratory muscles during intense physical exertion in patients with CHF may increase respiratory failure and provoke hyperactivation of the inspiratory metaboreflex, thereby aggravating exercise intolerance due to a decrease in muscular-muscular system perfusion due to redistribution of blood flow. In addition, it was shown that fatigue of the respiratory muscles increases the activity of the sympathetic nervous system and reduces blood flow in the muscles of the inactive limb due to adrenergic vasoconstriction. This response is most likely associated with metabolic stimulation of small afferent type III and IV fibers of the respiratory muscles, especially the diaphragm. Respiratory muscle training can minimize the effects of inspiration metaboreflex activation and prolong the duration of exercise. In addition, several studies have shown that the strength of the respiratory muscles in patients with HF correlates with central hemodynamic indices at rest, including cardiac output, mean pulmonary pressure and pulmonary vascular resistance. Several studies have shown that the mechanism that improves exercise tolerance in patients with HF after training the respiratory muscles is to increase the blood supply to the muscles of the limbs at rest and during exercise. Thus, the mechanisms of the effect of the weakness of the respiratory muscles on the pathogenesis of a decrease in the functional ability of patients are well studied. Both respiratory muscular and aerobic exercises of moderate effectiveness are recommended by leading medical communities as an effective means to improve the functional ability of patients, improve quality of life parameters, improve symptoms and reduce hospital admissions (level of evidence Level 1). At the same time, respiratory muscle training is recommended as the beginning of physical rehabilitation in patients with IV FC HF, and moderate-intensity aerobic training is recommended for patients with FC I-III FC. Also, in individual works abroad, the effects of respiratory muscle training on clinical CHF. However, according to the investigator's information, no studies have been carried out on the study of the method of functional training, including training of the respiratory muscles, as an obligatory initial stage of physical rehabilitation of patients with any functional class of HF.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure
Keywords
CHF, exercise, aerobic, respiratory muscle training

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Parallel assignment
Masking
ParticipantOutcomes Assessor
Masking Description
The control group will be assigned an imitation of respiratory muscles training with the help of breathing simulators, with a breathing resistance level set at 0
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
respiratory muscles training
Arm Type
Experimental
Arm Description
4 weeks guided respiratory muscles training followed by 12 weeks guided aerobic training - (treadmill walking)
Arm Title
sham respiratory muscles training
Arm Type
Sham Comparator
Arm Description
4 weeks sham respiratory muscles training (THRESHOLD® IMT breathing trainer with "0" pressure level) followed by 12 weeks guided aerobic training - (treadmill walking)
Intervention Type
Other
Intervention Name(s)
respiratory muscles training
Intervention Description
4 weeks respiratory muscles training aimed on respiratory muscles endurance and lengthening expiration time
Intervention Type
Other
Intervention Name(s)
sham respiratory muscles training
Intervention Description
4 weeks sham respiratory muscles training with the help of breathing simulators, with a breathing resistance level set at 0
Intervention Type
Other
Intervention Name(s)
aerobic training
Intervention Description
12 weeks treadmill walking
Primary Outcome Measure Information:
Title
Functional Capacity
Description
Change in Peak VO2
Time Frame
16 weeks
Secondary Outcome Measure Information:
Title
proBNP
Description
Change in concentration of NT- proBNP from baseline
Time Frame
4 weeks
Title
proBNP
Description
Change in concentration of NT- proBNP from baseline
Time Frame
16 weeks
Title
Respiratory muscle strength
Description
Change in maximal inspiratory and expiratory pressures (PImax and PEmax) from baseline
Time Frame
4 weeks
Title
Respiratory muscle strength
Description
Change in maximal inspiratory and expiratory pressures (PImax and PEmax) from baseline
Time Frame
16 weeks
Title
Neurohormone activity
Description
Difference between Active and Control groups in Angiotensin II (A II) concentration from baseline
Time Frame
4 weeks
Title
Neurohormone activity
Description
Change in concentration of Angiotensin II (A II) from baseline
Time Frame
16 weeks
Other Pre-specified Outcome Measures:
Title
Change in health-related quality of life
Description
Minnesota Living with Heart Failure Questionnaire/ The quality of life between study groups and the change in quality of life over time between study groups.
Time Frame
4 weeks
Title
Change in health-related quality of life
Description
Minnesota Living with Heart Failure Questionnaire. Assessed from baseline visit to 16 weeks follow-up visit.The quality of life between study groups and the change in quality of life over time between study groups using clinically accepted quality of life measures. MLHFQ
Time Frame
16 weeks
Title
Anxiety and Depression
Description
Hospital Anxiety sand Depression Scale (HADS) The questionnaire comprises seven questions for anxiety and seven questions for depression.Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21. The cut off for both scales in 11.
Time Frame
4 weeks
Title
Anxiety and Depression
Description
Hospital Anxiety sand Depression Scale (HADS) The questionnaire comprises seven questions for anxiety and seven questions for depression.Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21. The cut off for both scales in 11.
Time Frame
16 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female patients aged 18 years and older (inclusive) Patients with stable heart failure of the II-III functional class. Signed patient informed consent to participate in the study. Left ventricular ejection fraction ≤40%, confirmed by the results of EchoCG no more than 3 months before the start of the study. Patients who can understand the objectives of this study and comply with the requirements of the Protocol. Exclusion Criteria: • Heart failure I and VI functional class Left ventricular ejection fraction> 41% or no confirmed data on the left ventricular EF. Myocardial infarction, ACS, heart surgery, percutaneous coronary intervention, or coronary artery bypass surgery performed less than 3 months prior to randomization. Unstable or refractory angina. Pulmonary heart. Constrictive pericarditis. Hypertrophic cardiomyopathy. Amyloid cardiomyopathy. Syndrome of premature excitation of the ventricles. The need for percutaneous coronary intervention or coronary bypass surgery in the near future. Sinus node dysfunction syndrome. The presence of a pacemaker. The presence of diagnosed non-cardiac causes of CHF. Any non-cardiac disease that reduces the expected duration to less than 2 years from the moment of randomization. A stroke less than 1 month prior to randomization or a stroke with marked continuing neurological disorders less than 12 months before randomization Orthopedic disorders that prevent physical training COPD, Bronchial asthma. Another lung disease that can affect CSTP results Significant impaired renal function (plasma creatinine 220 µmol / L or higher). Significant abnormal liver function (increased ALT or AST more than 3 times relative to the upper limit of normal). Acute coronary syndrome less than 3 months before randomization. Obstructive or restrictive cardiomyopathy. Acute myocarditis. Hemodynamically significant organic lesions of valves requiring surgical intervention. A history of heart transplantation or current waiting for a heart transplant. Drug addiction, substance abuse, alcoholism, drug use in history. Mental, physical and other reasons that do not allow to adequately assess their behavior and correctly fulfill the conditions of the study protocol. A history of any significant, in the opinion of the physician-researcher, condition / disease or circumstances that prevent the inclusion in the study. Inability / reluctance of the patient to provide signed informed consent to participate in the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yana A Orlova, Professor
Organizational Affiliation
Moscow State University
Official's Role
Study Chair
Facility Information:
Facility Name
Julia Begrambekova
City
Moscow
State/Province
Moscow Region
ZIP/Postal Code
119620
Country
Russian Federation

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Complex Exercises of the Respiratory Muscles Plus Aerobic Training vs. Aerobic Training in Patients With СHF

We'll reach out to this number within 24 hrs